

Psychedelic Drugs-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/P260115C0338EN.html>

Date: December 2021

Pages: 149

Price: US\$ 3,680.00 (Single User License)

ID: P260115C0338EN

Abstracts

Report Summary

Psychedelic Drugs-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Psychedelic Drugs industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Psychedelic Drugs 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of Psychedelic Drugs worldwide and market share by regions, with company and product introduction, position in the Psychedelic Drugs market

Market status and development trend of Psychedelic Drugs by types and applications
Cost and profit status of Psychedelic Drugs, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Psychedelic Drugs market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive

slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Psychedelic Drugs industry.

The report segments the global Psychedelic Drugs market as:

Global Psychedelic Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Psychedelic Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):

Psilocybin

LSD

MDMA

DMT

Ketamine

Others

Global Psychedelic Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)

Depressive Disorders

Post-Traumatic Stress Disorders

Substance Abuse Disorders

Obsessive Compulsive Disorders

Others

Global Psychedelic Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Psychedelic Drugs Sales Volume, Revenue, Price and Gross Margin):

COMPASS Pathways PLC

Pfizer

Eli Lilly

GlaxoSmithKline

Cybin Inc

Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Janssen
Acadia Pharmaceuticals
Intellipharma
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PSYCHEDELIC DRUGS

- 1.1 Definition of Psychedelic Drugs in This Report
- 1.2 Commercial Types of Psychedelic Drugs
 - 1.2.1 Psilocybin
 - 1.2.2 LSD
 - 1.2.3 MDMA
 - 1.2.4 DMT
 - 1.2.5 Ketamine
 - 1.2.6 Others
- 1.3 Downstream Application of Psychedelic Drugs
 - 1.3.1 Depressive Disorders
 - 1.3.2 Post-Traumatic Stress Disorders
 - 1.3.3 Substance Abuse Disorders
 - 1.3.4 Obsessive Compulsive Disorders
 - 1.3.5 Others
- 1.4 Development History of Psychedelic Drugs
- 1.5 Market Status and Trend of Psychedelic Drugs 2016-2026
 - 1.5.1 Global Psychedelic Drugs Market Status and Trend 2016-2026
 - 1.5.2 Regional Psychedelic Drugs Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Psychedelic Drugs 2016-2021
- 2.2 Sales Market of Psychedelic Drugs by Regions
 - 2.2.1 Sales Volume of Psychedelic Drugs by Regions
 - 2.2.2 Sales Value of Psychedelic Drugs by Regions
- 2.3 Production Market of Psychedelic Drugs by Regions
- 2.4 Global Market Forecast of Psychedelic Drugs 2022-2026
 - 2.4.1 Global Market Forecast of Psychedelic Drugs 2022-2026
 - 2.4.2 Market Forecast of Psychedelic Drugs by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Psychedelic Drugs by Types
- 3.2 Sales Value of Psychedelic Drugs by Types
- 3.3 Market Forecast of Psychedelic Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Psychedelic Drugs by Downstream Industry
- 4.2 Global Market Forecast of Psychedelic Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Psychedelic Drugs Market Status by Countries
 - 5.1.1 North America Psychedelic Drugs Sales by Countries (2016-2021)
 - 5.1.2 North America Psychedelic Drugs Revenue by Countries (2016-2021)
 - 5.1.3 United States Psychedelic Drugs Market Status (2016-2021)
 - 5.1.4 Canada Psychedelic Drugs Market Status (2016-2021)
 - 5.1.5 Mexico Psychedelic Drugs Market Status (2016-2021)
- 5.2 North America Psychedelic Drugs Market Status by Manufacturers
- 5.3 North America Psychedelic Drugs Market Status by Type (2016-2021)
 - 5.3.1 North America Psychedelic Drugs Sales by Type (2016-2021)
 - 5.3.2 North America Psychedelic Drugs Revenue by Type (2016-2021)
- 5.4 North America Psychedelic Drugs Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Psychedelic Drugs Market Status by Countries
 - 6.1.1 Europe Psychedelic Drugs Sales by Countries (2016-2021)
 - 6.1.2 Europe Psychedelic Drugs Revenue by Countries (2016-2021)
 - 6.1.3 Germany Psychedelic Drugs Market Status (2016-2021)
 - 6.1.4 UK Psychedelic Drugs Market Status (2016-2021)
 - 6.1.5 France Psychedelic Drugs Market Status (2016-2021)
 - 6.1.6 Italy Psychedelic Drugs Market Status (2016-2021)
 - 6.1.7 Russia Psychedelic Drugs Market Status (2016-2021)
 - 6.1.8 Spain Psychedelic Drugs Market Status (2016-2021)
 - 6.1.9 Benelux Psychedelic Drugs Market Status (2016-2021)
- 6.2 Europe Psychedelic Drugs Market Status by Manufacturers
- 6.3 Europe Psychedelic Drugs Market Status by Type (2016-2021)
 - 6.3.1 Europe Psychedelic Drugs Sales by Type (2016-2021)

- 6.3.2 Europe Psychedelic Drugs Revenue by Type (2016-2021)
- 6.4 Europe Psychedelic Drugs Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Psychedelic Drugs Market Status by Countries
 - 7.1.1 Asia Pacific Psychedelic Drugs Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific Psychedelic Drugs Revenue by Countries (2016-2021)
 - 7.1.3 China Psychedelic Drugs Market Status (2016-2021)
 - 7.1.4 Japan Psychedelic Drugs Market Status (2016-2021)
 - 7.1.5 India Psychedelic Drugs Market Status (2016-2021)
 - 7.1.6 Southeast Asia Psychedelic Drugs Market Status (2016-2021)
 - 7.1.7 Australia Psychedelic Drugs Market Status (2016-2021)
- 7.2 Asia Pacific Psychedelic Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Psychedelic Drugs Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific Psychedelic Drugs Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific Psychedelic Drugs Revenue by Type (2016-2021)
- 7.4 Asia Pacific Psychedelic Drugs Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Psychedelic Drugs Market Status by Countries
 - 8.1.1 Latin America Psychedelic Drugs Sales by Countries (2016-2021)
 - 8.1.2 Latin America Psychedelic Drugs Revenue by Countries (2016-2021)
 - 8.1.3 Brazil Psychedelic Drugs Market Status (2016-2021)
 - 8.1.4 Argentina Psychedelic Drugs Market Status (2016-2021)
 - 8.1.5 Colombia Psychedelic Drugs Market Status (2016-2021)
- 8.2 Latin America Psychedelic Drugs Market Status by Manufacturers
- 8.3 Latin America Psychedelic Drugs Market Status by Type (2016-2021)
 - 8.3.1 Latin America Psychedelic Drugs Sales by Type (2016-2021)
 - 8.3.2 Latin America Psychedelic Drugs Revenue by Type (2016-2021)
- 8.4 Latin America Psychedelic Drugs Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Psychedelic Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa Psychedelic Drugs Sales by Countries (2016-2021)
 - 9.1.2 Middle East and Africa Psychedelic Drugs Revenue by Countries (2016-2021)
 - 9.1.3 Middle East Psychedelic Drugs Market Status (2016-2021)
 - 9.1.4 Africa Psychedelic Drugs Market Status (2016-2021)
- 9.2 Middle East and Africa Psychedelic Drugs Market Status by Manufacturers
- 9.3 Middle East and Africa Psychedelic Drugs Market Status by Type (2016-2021)
 - 9.3.1 Middle East and Africa Psychedelic Drugs Sales by Type (2016-2021)
 - 9.3.2 Middle East and Africa Psychedelic Drugs Revenue by Type (2016-2021)
- 9.4 Middle East and Africa Psychedelic Drugs Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PSYCHEDELIC DRUGS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Psychedelic Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 PSYCHEDELIC DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Psychedelic Drugs by Major Manufacturers
- 11.2 Production Value of Psychedelic Drugs by Major Manufacturers
- 11.3 Basic Information of Psychedelic Drugs by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Psychedelic Drugs Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Psychedelic Drugs Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 PSYCHEDELIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 COMPASS Pathways PLC
 - 12.1.1 Company profile
 - 12.1.2 Representative Psychedelic Drugs Product
 - 12.1.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of COMPASS Pathways PLC

12.2 Pfizer

12.2.1 Company profile

12.2.2 Representative Psychedelic Drugs Product

12.2.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Pfizer

12.3 Eli Lilly

12.3.1 Company profile

12.3.2 Representative Psychedelic Drugs Product

12.3.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly

12.4 GlaxoSmithKline

12.4.1 Company profile

12.4.2 Representative Psychedelic Drugs Product

12.4.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of

GlaxoSmithKline

12.5 Cybin Inc

12.5.1 Company profile

12.5.2 Representative Psychedelic Drugs Product

12.5.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Cybin Inc

12.6 Field Trip Health

12.6.1 Company profile

12.6.2 Representative Psychedelic Drugs Product

12.6.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Field Trip

Health

12.7 ATAI Life Sciences

12.7.1 Company profile

12.7.2 Representative Psychedelic Drugs Product

12.7.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of ATAI Life

Sciences

12.8 NUMINUS WELLNESS

12.8.1 Company profile

12.8.2 Representative Psychedelic Drugs Product

12.8.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of NUMINUS

WELLNESS

12.9 MindMed

12.9.1 Company profile

12.9.2 Representative Psychedelic Drugs Product

12.9.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of MindMed

12.10 HAVN Life Sciences

12.10.1 Company profile

12.10.2 Representative Psychedelic Drugs Product

12.10.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of HAVN Life Sciences

12.11 Seelos Therapeutics

12.11.1 Company profile

12.11.2 Representative Psychedelic Drugs Product

12.11.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Seelos Therapeutics

12.12 Janssen

12.12.1 Company profile

12.12.2 Representative Psychedelic Drugs Product

12.12.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Janssen

12.13 Acadia Pharmaceuticals

12.13.1 Company profile

12.13.2 Representative Psychedelic Drugs Product

12.13.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Acadia Pharmaceuticals

12.14 Intellipharma

12.14.1 Company profile

12.14.2 Representative Psychedelic Drugs Product

12.14.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Intellipharma

12.15 Revive Therapeutics

12.15.1 Company profile

12.15.2 Representative Psychedelic Drugs Product

12.15.3 Psychedelic Drugs Sales, Revenue, Price and Gross Margin of Revive Therapeutics

12.16 Mydecine Innovations Group

12.17 Red Light Holland

12.18 Braxia Scientific

12.19 Mind Cure Health

12.20 Enttheon Biomedical

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PSYCHEDELIC DRUGS

13.1 Industry Chain of Psychedelic Drugs

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PSYCHEDELIC DRUGS

- 14.1 Cost Structure Analysis of Psychedelic Drugs
- 14.2 Raw Materials Cost Analysis of Psychedelic Drugs
- 14.3 Labor Cost Analysis of Psychedelic Drugs
- 14.4 Manufacturing Expenses Analysis of Psychedelic Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Psychedelic Drugs-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/P260115C0338EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P260115C0338EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

